Investor Relations Home

Corporate Profile

Here you will find financial reports and shareholder information about Omeros Corporation, including recent news, current and historical share price, and electronic copies of our SEC filings.

Stock Quote

(Common Stock)
Exchange (US Dollar)
Change (%)   
Data as of  

Copyright West LLC. Minimum 15 minutes delayed.

More >>

Recent Press Releases

07/11/19 Omeros Announces Agreement with FDA on Primary Endpoint for Narsoplimab BLA in Stem Cell Transplant-Associated TMA
-- All Criteria for the Response-Based Endpoint Now Finalized -- SEATTLE --(BUSINESS WIRE)--Jul. 11, 2019-- Omeros Corporation today announced agreement with the U.S. Food and Drug Administration ( FDA ) on the response-based primary endpoint for its pivotal trial to support the biologics license
06/05/19 Omeros Corporation Announces Assignment of Rapporteurs for European Marketing Authorization Application for Narsoplimab for Treatment of HSCT-TMA
– Preparations Continue for Submission of BLA in the U.S. and MAA in Europe – SEATTLE --(BUSINESS WIRE)--Jun. 5, 2019-- Omeros Corporation (Nasdaq: OMER) today announced that the European Medicines Agency (EMA) has appointed rapporteurs for the company’s marketing authorization application (MAA)
05/15/19 Omeros to Present at the UBS Global Healthcare Conference
SEATTLE --(BUSINESS WIRE)--May 15, 2019-- Omeros Corporation (NASDAQ: OMER) today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the UBS Global Healthcare Conference in New York next week. The presentation is scheduled for Wednesday, May 22, 2019 at
05/09/19 Omeros Corporation Reports First Quarter 2019 Financial Results
– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--May 9, 2019-- Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan